MAPT and Alzheimer disease: Since MARK4 is closely related to hyperphosphorylation at Ser262 in AD mice, our results thus suggest that dl-NBP could target the tau kinase MARK4 and, in turn, result in the downregulation of hyperphosphorylation tau at the site of Ser262.